COVID-19 adenovirus vector vaccine (Rong'an Biological)

The COVID-19 adenovirus vector vaccine is a preclinical-stage vaccine candidate developed by Rong'an Biological, a subsidiary of AIM Vaccine. It utilizes an adenovirus vector platform to deliver the genetic sequence of the SARS-CoV-2 spike protein into the recipient's cells. Once inside, the cells produce the spike protein, which then triggers the immune system to generate antibodies and T-cell responses. This specific candidate is designed with a broad-spectrum intent, aiming to provide protection against a wide range of SARS-CoV-2 variants. It is part of AIM Vaccine's diversified COVID-19 vaccine pipeline, which also includes mRNA and inactivated vaccine technologies.

Other names

Broad-spectrum adenovirus-vectored COVID-19 vaccineRong'an COVID-19 adenovirus vaccine